Abstract
Summary
LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism. We hypothesized that gain-of-function mutations in LRP5 would also affect these parameters. We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
Introduction
Wnt signaling through LRP5 represents a newly appreciated metabolic pathway, which potentially represents a target for drug discovery in type 2 diabetes and hyperlipidemia. Studies in animal models suggest a physiologic link between LRP5 and glucose and lipid homeostasis; however, whether it plays a similar role in humans is unclear. As current literature links loss-of-function LRP5 to impaired glucose and lipid metabolism, we hypothesized that individuals with an HBM-causing mutation in LRP5 would exhibit improved glucose and lipid homeostasis. Since studies in animal models have suggested that Wnt signaling augments insulin secretion, we also examined the effect of Wnt signaling on glucose-stimulated insulin secretion on human pancreatic islets.
Methods
This was a matched case-control study. We used several methods to assess glucose and lipid metabolism in 11 individuals with HBM-causing mutations in LRP5. Affected study participants were recruited from previously identified kindreds with HBM-causing LRP5 mutations and included 9 males and 2 females. Two subjects that were being treated with insulin for type 2 diabetes were excluded from our analysis, as this would have obscured our ability to determine the impact of gain-of-function LRP5 mutations on glucose metabolism. The mean age of the evaluated study subjects was 55 ± 7 with a mean BMI of 27.2 ± 2.0. Control subjects were matched and recruited from the general community at an equivalent ratio, with 18 males and 4 females (mean age 56 ± 4; mean BMI 27.2 ± 1.0). Study testing was conducted at an academic medical center.
Results
There were no statistically significant differences between affected and matched control populations for HbA1c (p = 0.06), eAG (p = 0.06), insulin (p = 0.82), HOMA-B (p = 0.34), or HOMA-IR (p = 0.66). The mean Insulin Sensitivity Index (ISI) was also similar between control and affected individuals. Total cholesterol (p = 0.43), triglycerides (TG) (p = 0.56), and HDL (p = 0.32) were not different between the same two groups. In a small subset of studied subjects, intramyocellular and hepatic lipid content were similar in the affected individuals and controls when quantified by proton magnetic resonance spectroscopy (MRS). However, the mean value for serum LDL was significantly lower (p = 0.04) in affected individuals. In primary human islets, there were no differences between control and Wnt treatment groups for insulin secretion measured as area under the curve (AUC) for first phase (p = 0.17) or second phase (p = 0.33) insulin secretion.
Conclusions
Although our sample size was small, our data do not support the hypothesis that HBM-causing LRP5 mutations, associated with increased Wnt signaling, improve glucose metabolism in humans. However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease. The molecular mechanisms underpinning this effect warrant further study.
References
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127(3):469–480
Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4):513–523
Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA et al (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513–1521
Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S et al (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A 100(1):229–234
Saarinen A, Saukkonen T, Kivela T, Lahtinen U, Laine C, Somer M et al (2010) Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin Endocrinol 72(4):481–488
Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A et al (2003) Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 278(13):11331–11336
Giusti B, Rossi L, Lapini I, Magi A, Pratesi G, Lavitrano M et al (2009) Gene expression profiling of peripheral blood in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 38(1):104–112
Jiang XY, Chen Y, Xu L, Li X, Cao FF, Li L et al (2010) Association of LPR5 polymorphism with bone mass density and cholesterol level in population of Chinese Han. Exp Clin Endocrinol Diabetes 118(6):388–391
Lappalainen S, Saarinen A, Utriainen P, Voutilainen R, Jaaskelainen J, Makitie O (2009) LRP5 in premature adrenarche and in metabolic characteristics of prepubertal children. Clin Endocrinol 70(5):725–731
Zenibayashi M, Miyake K, Horikawa Y, Hirota Y, Teranishi T, Kouyama K et al (2008) Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in the Japanese population. Endocr J 55(4):699–707
Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, et al. 2013 Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5. J Bone Miner Res
Ai M, Holmen SL, Hul WV, Williams BO, Warman ML (2005) Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25(12):4946–4955
Boyden LM, Insogna K, Lifton RP (2004) High-bone-mass disease and LRP5. N Engl J Med 350(20):2096–2099
Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D et al (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) Gene in different conditions with an increased bone density. Am J Hum Genet 72(3):763–771
Peterson KF, Morino K, Alves TC, Kibbey RG, Dufour S, Sono S, Yoo PS, Cline GW, Shulman GI (2015) Effect of aging on muscle mitochondrial substrate utilization in humans. PNAS 112(36):11330–11334
Flannery C, Dufour S, Rabol R, Shulman GI, Peterson KF (2012) Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 61(11):2711–2717
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502
Rabol R, Petersen KF, Dufour S, Flannery C, Shulman GI (2011) Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A 108(33):13705–13709
Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(Suppl 2):S9–s15
Pigeau GM, Kolic J, Ball BJ, Hoppa MB, Wang YW, Ruckle T et al (2009) Insulin granule recruitment and exocytosis is dependent on p110gamma in insulinoma and human beta-cells. Diabetes 58(9):2084–2092
Cabrera O, Jacques-Silva MC, Berman DM, Fachado A, Echeverri F, Poo R et al (2008) Automated, high-throughput assays for evaluation of human pancreatic islet function. Cell Transplant 16(10):1039–1048
Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL et al (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60(3):890–898
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350(7):664–671
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31(8):1473–1478
Hey PJ, Twells RC, Phillips MS, Yusuke N, Brown SD, Kawaguchi Y et al (1998) Cloning of a novel member of the low-density lipoprotein receptor family. Gene 216(1):103–111
Palsgaard J, Emanuelli B, Winnay JN, Sumara G, Karsenty G, Kahn CR (2012) Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). J Biol Chem 287(15):12016–12026
Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL et al (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42(1):113–116
Centers for Disease Control and Prevention (2014) National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. U.S. Department of Health and Human Services, Atlanta, GA, p 2014
Steiner DJ, Kim A, Miller K, Hara M (2010) Pancreatic islet plasticity: interspecies comparison of islet architecture and composition. Islets 2(3):135–145
Kim DH, Inagaki Y, Suzuki T, Ioka RX, Yoshioka SZ, Magoori K et al (1998) A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem 124(6):1072–1076
Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS (1994) The two-receptor model of lipoprotein clearance: tests of the hypothesis in “knockout” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A 91(10):4431–4435
Van Meurs JBJ, Trikalinos TA, Ralston SH et al (2008) Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299(11):1277–1290
Acknowledgements
We thank Sylvie Dufour, Ph.D., Anne Impellizeri, B.S., Irina Smolgovsky, and the staff of the Yale Center for Clinical Investigation, Hospital Research Unit, for their expert support with these studies. We are also deeply indebted to the families and volunteers who so generously agreed to participate in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Grant support
This study was supported by the National Institutes of Health Grants NIH R01 DK092606 (R.G.K.), R01 AG-23686 (K.F.P.), a Distinguished Clinical Investigator Award from the American Diabetes Association (K.F.P), the Novo-Nordisk Center for Basic Metabolic Research (K.F.P.), the National Center For Advancing Translational Sciences of the NIH TL1TR000141 (D.F.), and the Yale Bone Center (DF, KLI).
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Foer, D., Zhu, M., Cardone, R.L. et al. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. Osteoporos Int 28, 2011–2017 (2017). https://doi.org/10.1007/s00198-017-3977-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-017-3977-4